Banque Transatlantique SA Has $41.26 Million Stake in Amgen Inc. $AMGN

Key Points

• Banque Transatlantique SA increased its investment in Amgen Inc. by 8,269.9% in the first quarter, acquiring an additional 141,580 shares, bringing its total to 143,292 shares valued at $41.26 million.
• Amgen's recent earnings report revealed earnings per share of $6.02, exceeding expectations, with a reported revenue of $9.18 billion, reflecting a 9.4% year-over-year increase.
• Amgen announced a quarterly dividend of $2.38, with a dividend yield of 3.3%, indicating a payout ratio of 77.84%.

Banque Transatlantique SA lifted its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 8,269.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 143,292 shares of the medical research company's stock after purchasing an additional 141,580 shares during the quarter. Amgen accounts for about 0.8% of Banque Transatlantique SA's investment portfolio, making the stock its 25th biggest holding. Banque Transatlantique SA's holdings in Amgen were worth $41,256,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of AMGN. Vanguard Group Inc. boosted its stake in shares of Amgen by 0.3% in the first quarter. Vanguard Group Inc. now owns 52,870,453 shares of the medical research company's stock worth $16,471,790,000 after acquiring an additional 148,658 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Amgen by 15.4% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,128,328 shares of the medical research company's stock worth $1,336,647,000 after buying an additional 685,785 shares during the period. Royal Bank of Canada grew its stake in Amgen by 6.0% in the first quarter. Royal Bank of Canada now owns 4,883,134 shares of the medical research company's stock worth $1,521,339,000 after purchasing an additional 274,488 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in Amgen by 5.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 4,454,164 shares of the medical research company's stock valued at $1,387,695,000 after acquiring an additional 243,306 shares in the last quarter. Finally, GAMMA Investing LLC boosted its position in Amgen by 43,573.5% during the 1st quarter. GAMMA Investing LLC now owns 3,661,589 shares of the medical research company's stock valued at $1,140,768,000 after acquiring an additional 3,653,205 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company's stock.

Insider Buying and Selling

In other news, SVP Nancy A. Grygiel sold 1,267 shares of the firm's stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total value of $376,286.33. Following the transaction, the senior vice president owned 7,209 shares of the company's stock, valued at approximately $2,141,000.91. This trade represents a 14.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.76% of the stock is currently owned by corporate insiders.

Amgen Price Performance

Shares of AMGN stock traded up $3.54 during midday trading on Friday, reaching $283.64. 2,299,355 shares of the company were exchanged, compared to its average volume of 1,790,560. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31. The company's 50 day moving average price is $293.85 and its two-hundred day moving average price is $292.60. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $339.17. The company has a market cap of $152.70 billion, a P/E ratio of 23.19, a PEG ratio of 2.46 and a beta of 0.49.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.28 by $0.74. The business had revenue of $9.18 billion for the quarter, compared to analyst estimates of $8.86 billion. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The firm's revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $4.97 earnings per share. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. On average, sell-side analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, September 12th. Investors of record on Friday, August 22nd will be given a dividend of $2.38 per share. The ex-dividend date is Friday, August 22nd. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.4%. Amgen's dividend payout ratio (DPR) is 77.84%.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Cantor Fitzgerald reiterated a "neutral" rating and set a $305.00 price objective on shares of Amgen in a research note on Tuesday, June 24th. Citigroup boosted their target price on Amgen from $305.00 to $310.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Raymond James Financial assumed coverage on Amgen in a research report on Wednesday. They set a "market perform" rating on the stock. Morgan Stanley upped their price objective on shares of Amgen from $330.00 to $333.00 and gave the company an "equal weight" rating in a research note on Wednesday, August 6th. Finally, William Blair reiterated an "outperform" rating on shares of Amgen in a research note on Tuesday, June 24th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Amgen has a consensus rating of "Hold" and an average target price of $304.43.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.